{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:09:05Z","timestamp":1778623745492,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jsat.2017.01.015","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T13:32:49Z","timestamp":1485523969000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Retention in buprenorphine treatment is associated with improved HCV care outcomes"],"prefix":"10.1016","volume":"75","author":[{"given":"B.L.","family":"Norton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Beitin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.O.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2017.01.015_bb0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0168-8278(99)80381-X","article-title":"Hepatitis C virus infection in the United States","volume":"31","author":"Alter","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2017.01.015_bb0010","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","article-title":"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: Results from a multisite study","volume":"56","author":"Altice","year":"2011","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"10","key":"10.1016\/j.jsat.2017.01.015_bb0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2017.01.015_bb0020","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1081\/ADA-200037544","article-title":"Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services","volume":"30","author":"Astone","year":"2004","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"11","key":"10.1016\/j.jsat.2017.01.015_bb0025","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1111\/j.1572-0241.2008.02065.x","article-title":"Efficacy and safety of peginterferon alfa-2a\/ribavirin in methadone maintenance patients: Randomized comparison of direct observed therapy and self-administration","volume":"103","author":"Bonkovsky","year":"2008","journal-title":"The American Journal of Gastroenterology"},{"issue":"Suppl. 2","key":"10.1016\/j.jsat.2017.01.015_bb0030","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all","volume":"57","author":"Bruggmann","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2017.01.015_bb0035","series-title":"Surveillance for Viral Hepatitis 2013","author":"Centers for Disease Control and Prevention","year":"2013"},{"issue":"8","key":"10.1016\/j.jsat.2017.01.015_bb0040","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","article-title":"Hepatitis C virus infection in USA: An estimate of true prevalence","volume":"31","author":"Chak","year":"2011","journal-title":"Liver International"},{"issue":"7","key":"10.1016\/j.jsat.2017.01.015_bb0045","first-page":"500","article-title":"Buprenorphine treatment in an urban community health center: What to expect","volume":"40","author":"Cunningham","year":"2008","journal-title":"Family Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.015_bb0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJM200107193450312","article-title":"Treatment of chronic hepatitis C in active drug users","volume":"345","author":"Davis","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2017.01.015_bb0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jsat.2017.01.015_bb0060","series-title":"C-EDGE CO-STAR: Efficacy of Grazoprevir and Elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy. Paper presented at the AASLD Liver Meeting, San Francisco, CA","author":"Dore","year":"2015"},{"key":"10.1016\/j.jsat.2017.01.015_bb0065","series-title":"Drug enforcement administration office of diversion control","author":"Drug Enforcement Administration (DEA). Buprenorphine","year":"2013"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.015_bb0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJM200107193450311","article-title":"Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?","volume":"345","author":"Edlin","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2017.01.015_bb0075","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/QAI.0b013e3182097537","article-title":"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine\/naloxone","volume":"56","author":"Fiellin","year":"2011","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"5","key":"10.1016\/j.jsat.2017.01.015_bb0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.drugpo.2007.01.009","article-title":"Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection","volume":"18","author":"Grebely","year":"2007","journal-title":"The International Journal on Drug Policy"},{"issue":"10","key":"10.1016\/j.jsat.2017.01.015_bb0085","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/aje\/kwn237","article-title":"Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place","volume":"168","author":"Hagan","year":"2008","journal-title":"American Journal of Epidemiology"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.015_bb0090","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1086\/649783","article-title":"Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities","volume":"201","author":"Hagan","year":"2010","journal-title":"The Journal of Infectious Diseases"},{"issue":"7","key":"10.1016\/j.jsat.2017.01.015_bb0095","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1440-1746.2005.03882.x","article-title":"Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy","volume":"20","author":"Hallinan","year":"2005","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"4","key":"10.1016\/j.jsat.2017.01.015_bb0100","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/600304","article-title":"Hepatitis C treatment for injection drug users: A review of the available evidence","volume":"49","author":"Hellard","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2017.01.015_bb0105","series-title":"New York city department of health and mental hygiene","author":"Hepatitis B and C Annual Report","year":"2016"},{"issue":"26","key":"10.1016\/j.jsat.2017.01.015_bb0110","first-page":"719","article-title":"Vital signs: Demographic and substance use trends among heroin users - United States, 2002\u20132013","volume":"64","author":"Jones","year":"2015","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"4","key":"10.1016\/j.jsat.2017.01.015_bb0115","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2010.12.032","article-title":"Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection","volume":"140","author":"Kanwal","year":"2011","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2017.01.015_bb0120","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/cid\/cis393","article-title":"Evolving epidemiology of hepatitis C virus in the United States","volume":"55","author":"Klevens","year":"2012","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1016\/j.jsat.2017.01.015_bb0125","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","volume":"63","author":"Lalezari","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1016\/j.jsat.2017.01.015_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097317","article-title":"The hepatitis C cascade of care: Identifying priorities to improve clinical outcomes","volume":"9","author":"Linas","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.jsat.2017.01.015_bb0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2008.09.009","article-title":"Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program","volume":"37","author":"Litwin","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10","key":"10.1016\/j.jsat.2017.01.015_bb0140","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.drugpo.2015.08.008","article-title":"Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program","volume":"26","author":"Litwin","year":"2015","journal-title":"The International Journal on Drug Policy"},{"issue":"4","key":"10.1016\/j.jsat.2017.01.015_bb0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.015_bb0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"Journal of Community Health"},{"issue":"1","key":"10.1016\/j.jsat.2017.01.015_bb0155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/00952990.2014.983274","article-title":"Association between hepatitis C virus and opioid use while in buprenorphine treatment: Preliminary findings","volume":"41","author":"Murphy","year":"2015","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2017.01.015_bb0160","series-title":"High HCV cure rates for drug users treated with DAAs at an urban primary care clinic. Paper presented at the CROI, Boston, MA","author":"Norton","year":"2016"},{"issue":"8","key":"10.1016\/j.jsat.2017.01.015_bb0165","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/605947","article-title":"Acute hepatitis C virus infection in young adult injection drug users: A prospective study of incident infection, resolution, and reinfection","volume":"200","author":"Page","year":"2009","journal-title":"The Journal of Infectious Diseases"},{"issue":"1","key":"10.1016\/j.jsat.2017.01.015_bb0170","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.dld.2010.05.006","article-title":"Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States","volume":"43","author":"Rein","year":"2011","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl. 2","key":"10.1016\/j.jsat.2017.01.015_bb0175","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/cid\/cit302","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"57","author":"Robaeys","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"10.1016\/j.jsat.2017.01.015_bb0180","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2893.2010.01327.x","article-title":"Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting","volume":"18","author":"Southern","year":"2011","journal-title":"Journal of Viral Hepatitis"},{"issue":"4","key":"10.1016\/j.jsat.2017.01.015_bb0185","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jsat.2012.08.007","article-title":"Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program","volume":"43","author":"Stein","year":"2012","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.015_bb0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/ADM.0b013e318257377f","article-title":"Buprenorphine for human immunodeficiency virus\/hepatitis C virus-coinfected patients: Does it serve as a bridge to hepatitis C virus therapy?","volume":"6","author":"Taylor","year":"2012","journal-title":"Journal of Addiction Medicine"},{"issue":"12","key":"10.1016\/j.jsat.2017.01.015_bb0195","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1365-2893.2009.01250.x","article-title":"Uptake and delivery of hepatitis C treatment in opiate substitution treatment: Perceptions of clients and health professionals","volume":"17","author":"Treloar","year":"2010","journal-title":"Journal of Viral Hepatitis"},{"issue":"7","key":"10.1016\/j.jsat.2017.01.015_bb0200","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1465-3362.2012.00468.x","article-title":"Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs","volume":"31","author":"Treloar","year":"2012","journal-title":"Drug and Alcohol Review"},{"issue":"4","key":"10.1016\/j.jsat.2017.01.015_bb0205","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cld.2006.08.012","article-title":"Hepatitis C virus and liver transplantation","volume":"10","author":"Verna","year":"2006","journal-title":"Clinics in Liver Disease"},{"key":"10.1016\/j.jsat.2017.01.015_bb0210","series-title":"President Obama proposes $1.1 billion in new funding to address the prescription opioid abuse and heroin use epidemic","author":"White House Office of the Press Secretary","year":"2016"},{"issue":"1","key":"10.1016\/j.jsat.2017.01.015_bb0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jsat.2010.04.001","article-title":"Factors associated with complicated buprenorphine inductions","volume":"39","author":"Whitley","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"17","key":"10.1016\/j.jsat.2017.01.015_bb0220","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged \u226430years - Kentucky, Tennessee, Virginia, and West Virginia, 2006\u20132012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR. Morbidity and Mortality Weekly Report"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216301489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216301489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:45:28Z","timestamp":1760039128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547216301489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":44,"alternative-id":["S0740547216301489"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2017.01.015","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retention in buprenorphine treatment is associated with improved HCV care outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2017.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}